Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel V Catenacci

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Oncologist|April 18, 2015
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapiesSiraj M Ali, Eric M Sanford, Samuel J Klempner, et al.
The Lancet. Oncology|March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyGhassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
JAMA Network Open|June 11, 2021
Structural Racism and JAMA Network OpenFrederick P Rivara, Steven M Bradley, Daniel V Catenacci, et al.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Cancer Discovery|October 6, 2017
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal AdenocarcinomaEirini Pectasides, Matthew D Stachler, Sarah Derks, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Oncologist|April 18, 2015
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapiesSiraj M Ali, Eric M Sanford, Samuel J Klempner, et al.
The Lancet. Oncology|March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyGhassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
JAMA Network Open|June 11, 2021
Structural Racism and JAMA Network OpenFrederick P Rivara, Steven M Bradley, Daniel V Catenacci, et al.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Cancer Discovery|October 6, 2017
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal AdenocarcinomaEirini Pectasides, Matthew D Stachler, Sarah Derks, et al.
Pageof 2